Bumrungrad Hospital Public (OTC:BUHPF) vs. AirSculpt Technologies (NASDAQ:AIRS) Head-To-Head Comparison

AirSculpt Technologies (NASDAQ:AIRS) and Bumrungrad Hospital Public (OTC:BUHPF) are both business services companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for AirSculpt Technologies and Bumrungrad Hospital Public, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AirSculpt Technologies	0	5	0	0	2.00
Bumrungrad Hospital Public	0	0	0	0	N/A

AirSculpt Technologies presently has a consensus target price of $5.50, suggesting a potential downside of 6.14%. Given AirSculpt Technologies’ higher possible upside, research analysts clearly believe AirSculpt Technologies is more favorable than Bumrungrad Hospital Public.

Profitability

This table compares AirSculpt Technologies and Bumrungrad Hospital Public’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AirSculpt Technologies	-1.77%	6.42%	2.63%
Bumrungrad Hospital Public	N/A	N/A	N/A

Insider and Institutional Ownership

91.5% of AirSculpt Technologies shares are held by institutional investors. Comparatively, 8.3% of Bumrungrad Hospital Public shares are held by institutional investors. 78.8% of AirSculpt Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares AirSculpt Technologies and Bumrungrad Hospital Public”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AirSculpt Technologies	$195.92 million	1.72	-$4.48 million	($0.07)	-83.71
Bumrungrad Hospital Public	N/A	N/A	N/A	C$3.08	2.73

Bumrungrad Hospital Public has lower revenue, but higher earnings than AirSculpt Technologies. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Bumrungrad Hospital Public, indicating that it is currently the more affordable of the two stocks.

Summary

AirSculpt Technologies beats Bumrungrad Hospital Public on 6 of the 9 factors compared between the two stocks.

About AirSculpt Technologies

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips, or other areas. The company’s body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.

About Bumrungrad Hospital Public

Bumrungrad Hospital Public Company Limited owns and operates healthcare-related entities in Thailand and internationally. It operates allergy, arrhythmia, behavioral health, breast, home service, heart valve, robotic surgery, rehabilitation, children’s, colorectal surgery, complex coronary artery intervention, cornea transplant, dental, diagnostic, dialysis, digestive disease, ear, nose, throat, emergency, endocrinology, diabetes, expatriate liaison, eye, fertility, gastrointestinal motility, health screening, holistic wound care, horizon regional cancer, hyperbaric oxygen therapy, nephrology, neuroscience, orthopedics, perinatal, plastic surgery, pulmonary, refractive surgery, robotic scoliosis, skin, sports medicine and joint, surgery, travel medicine, urology, scientific wellness, skin and aesthetic, and women’s centers. The company also operates breastfeeding, Yangon, COVID-19 recovery, comprehensive sleep, IVF, hearing and balance, medical, memory, new life healthy aging, Parkinson’s disease and movement disorders, pride, surgery, vaccine clinics. In addition, it provides spine institute, diagnostic radiology and nuclear medicine, esperance, heart institute, intensive care unit, neurocritical care, nutrition services, pharmacy services, and preventive genomics and integrative medicine services. Further, the company offers clinical research; hospital consulting and management; healthcare personnel development and training; healthcare referral; and digital platform services. Additionally, it is involved in the distribution of pharmaceutical and medical goods in specialized stores; development of software for healthcare services; holding of real estate assets; and manufacture and sale of vitamin supplements. Bumrungrad Hospital Public Company Limited was founded in 1975 and is based in Bangkok, Thailand.